Torrent Pharma’s Q1 profit rose 20% YoY to Rs 548 crore, backed by strong revenues and international growth momentum.

• US sales up 19%, India and Brazil both rise 11%, supporting strong overall international performance this quarter.
• EBITDA margin stood at 32.5%, adjusted to 32.9% excluding one-time costs; gross margins stayed firm at 76%.
• R&D spend increased 16% YoY to Rs 157 crore, maintaining focus on innovation with a stable 5% sales ratio.